AJP - Renal Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol (February 18, 2009). doi:10.1152/ajprenal.90746.2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
296/5/F1088    most recent
90746.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyer-Schwesinger, C.
Right arrow Articles by Meyer, T. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyer-Schwesinger, C.
Right arrow Articles by Meyer, T. N.
Submitted on December 15, 2008
Revised on January 30, 2009
Accepted on February 13, 2009

Rho-kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF{kappa}B p65 signaling

Catherine Meyer-Schwesinger1, Silke Dehde2, Claudia von Ruffer2, Stefan Gatzemeier2, Philipp Klug2, Ulrich O. Wenzel3, Rolf A.K. Stahl4, Friedrich Thaiss1, and Tobias N. Meyer2*

1 University Hospital Hamburg
2 University of Hamburg
3 University hospital Hamburg
4 Universitatskrankenhays Eppendorf

* To whom correspondence should be addressed. E-mail: t.meyer{at}uke.uni-hamburg.de.

Rho-kinase signaling regulates inflammatory cell migration and chemokine production. We therefore investigated mechanisms of Rho-kinase dependent inflammation in lipopolysaccharide (LPS)-induced renal failure. C57/BL6 mice received intraperitoneal LPS with or without daily treatment with specific Rho-kinase inhibitors (Y-27632 or HA-1077, 5 mg/kg). Rho-kinase inhibitors were applied in a preventive (12h or 1h prior to LPS) or a therapeutic (6h after LPS) scheme. Both protected renal function and decreased tubular injury in LPS treated mice. Enhanced Rho-kinase activity was inhibited by HA-1077 in capillary endothelial cells, inflammatory cells and tubuli by analysis of Rho-kinase substrate phosphorylation. Early neutrophil influx was reduced by HA-1077 without reduction of the proinflammatory cytokine TNF{alpha}. In contrast, HA-1077 decreased influx of monocytes/macrophages coinciding with reduced expression of the NF{kappa}B regulated chemokines CCL5 and CCL2. We therefore examined NF{kappa}B signal transduction and found that NF{kappa}B p65 phosphorylation and nuclear translocation were reduced by Rho-kinase inhibition. I{kappa}B{alpha} degradation was not altered during the first 6h but reduced by HA-1077 at later time points. NF{kappa}B p50 deficient mice were similarly protected from renal injury by Rho-kinase inhibition further supporting the prominent role for p65 in Rho-kinase inhibition. Together, these data suggest that Rho-kinase inhibition by preventive or therapeutic treatment effectively reduced endotoxic kidney injury in part by attenuation of NF{kappa}B p65 activation.




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
U. Panzer, O. M. Steinmetz, J.-E. Turner, C. Meyer-Schwesinger, C. von Ruffer, T. N. Meyer, G. Zahner, C. Gomez-Guerrero, R. M. Schmid, U. Helmchen, et al.
Resolution of renal inflammation: a new role for NF-{kappa}B1 (p50) in inflammatory kidney diseases
Am J Physiol Renal Physiol, August 1, 2009; 297(2): F429 - F439.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.